InvestorsHub Logo
Followers 9
Posts 920
Boards Moderated 0
Alias Born 04/21/2014

Re: KrakenTaken post# 20341

Friday, 12/08/2017 10:47:30 PM

Friday, December 08, 2017 10:47:30 PM

Post# of 37495
Kraken_FDA_will_likely_Approve_OMHEs_Topical_Pain_Analgesic_in_2018

OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:

(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.

(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.

(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.

(4) OMHE said on Dec 5, 2017 that "plan already in motion".

12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here


So IMO, approval will be granted in 2018.




OMHE PPS Ready to Rise to $1






Made Thousands into Millions..Now in Tens of Millions